Abstract:Background: Fine-needle aspiration (FNA) biopsy is typically used in conjunction with cytopathologic evaluation to differentiate between benign and malignant thyroid nodules. Even so, the cytology results for 20-30% of thyroid nodules are indeterminate. This study sought to evaluate the usefulness of next-generation sequencing (NGS)-based multi-gene panel testing for risk stratification and the differentiation of benign from malignant thyroid nodules. Methods: Thyroid nodule samples were obtained from a cohort of 359 patients who underwent FNA. An NGS-based multi-gene panel testing was conducted for these samples, in which single-nucleotide variants (SNVs) and small insertion/deletions (InDels) can be detected in 11 genes and fusion events can be identified in 5 genes. Surgical resection was conducted for 113 patients (113/359), and then histopathology results were obtained. Results: In comparison to cytology alone, the diagnostic sensitivity of NGS combination cytology increased from 0.7245 (95% CI: 0.6289-0.8032) to 0.898 (95% CI: 0.8223-0.9437); the associated AUC was 0.8303 (vs. Cytology AUC: 0.7622, P < 0.001). BRAF V600E was identified in 136 patients, of whom 79 underwent surgery and were diagnosed with papillary thyroid carcinoma (PTC) pathologically. TERT promoter mutations or BRAF / RAS co-mutations with other genes were identified in 5 patients, while 4 patients were diagnosed with malignant thyroid cancer using the pathological method. RAS mutations were identified in 27 patients, while 10 patients underwent surgery, which showed that 3 patients were classified as PTC and 7 cases were benign. In addition, 4 RET fusions, 1 RET activation mutation, and 3 TP53 inactivation mutations were identified in the remaining 8 patients who have not undergone surgery. Negative genetic test results or variants with uncertain significance were identified in 183 patients. Among these patients, 12 malignant thyroid tumors, including 11 PTC and 1 MTC, were diagnosed in 20 patients who received surgery. Conclusion: Thyroid nodules coupled with BRAF V600E , TERT promoter variants, BRAF / RAS co-mutations with other genes, RET fusions, and RET activating mutations were classified as high-risk. Nodules with RAS mutations ( NRAS , KRAS , HRAS ) and TP53 inactivating mutations were considered to be in the intermediate-risk group, while those with non-pathogenic mutations (negative and variants of uncertain significance) were placed in the low-risk group. When combined with cytopathology, NGS increases the sensitivity of diagnosing benign and malignant thyroid nodules, and the reference is useful for patient risk stratification.

The negative outlook: Long‐term follow up of ThyroSeq negative and low‐risk nodules

Outcomes of Indeterminate Thyroid Nodules Managed Nonoperatively after Molecular Testing

ThyroSeq overview on indeterminate thyroid nodules: An institutional experience

Risk stratification of ThyroSeq results in indeterminate thyroid lesions: A single‐institution experience of clinicopathologic correlation with cytologic findings

Outcomes of cytologically indeterminate thyroid nodules managed with Genomic Sequencing Classifier

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology

Performance of the AmpliSeq NGS Panel in Thyroid Nodules with Indeterminate Cytology

Evolutionary analysis of indeterminate cytology and risk of malignancy in a thyroid nodule unit.

Longitudinal Assessment of Quality of Life Following Molecular Testing for Indeterminate Thyroid Nodules

Fate of nondiagnostic thyroid fine needle aspirations

The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules

Multiplatform molecular test performance in indeterminate thyroid nodules

Diagnostic accuracy of Afirma Gene Expression Classifier, Afirma Gene Sequencing Classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis

Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules

Next generation sequence-based targeted somatic mutation analysis in thyroid nodules with pathologically diagnosed as indeterminate cytology

Utility of a Multigene Testing for Preoperative Evaluation of Indeterminate Thyroid Nodules: A Prospective Blinded Single Center Study in China

The role of the ThyGeNEXT oncogene panel used in combination with the expanded miRNA panel ThyraMIRv2 in Indeterminate thyroid nodules: A large, blinded, real‐world, observational study

Evaluating the clinical performance of an updated microRNA classifier in indeterminate and RAS -mutated thyroid nodule management: A multi-institutional study

Two Decades of Thyroid Nodule Cytology in Children: Malignancy Risk Assessment at a Tertiary Care Center

Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study

Repeatedly non-diagnostic thyroid nodules: the experience of two thyroid clinics